Theriva Biologics Reports Positive VIRAGE Phase 2b Results

Theriva Biologics ( (TOVX) ) just unveiled an announcement.

On March 31, 2025, Theriva Biologics announced positive outcomes from a second Independent Data Monitoring Committee (IDMC) review of the VIRAGE Phase 2b clinical trial for VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC). The review found VCN-01 to be well tolerated with an adverse event profile consistent with previous trials, indicating the feasibility of repeated dosing. This development could guide the design of a potential Phase 3 trial, impacting the company’s future clinical strategies and regulatory discussions.

More about Theriva Biologics

Theriva Biologics is a diversified clinical-stage company focused on developing therapeutics for cancer and related diseases in areas of high unmet need. The company’s lead candidates include VCN-01, an oncolytic adenovirus designed to replicate within tumor cells and degrade the tumor stroma barrier, SYN-004, which aims to prevent microbiome damage from antibiotics, and SYN-020, an enzyme formulation intended to treat both local gastrointestinal and systemic diseases.

YTD Price Performance: -30.91%

Average Trading Volume: 132,163

Technical Sentiment Signal: Strong Buy

Current Market Cap: $3.17M

For a thorough assessment of TOVX stock, go to TipRanks’ Stock Analysis page.